Blog

Top Pharma News - IgeaHub

Top Pharma News | May – June 2017

AstraZeneca’s Imfinzi (durvalumab) receives US FDA accelerated approval for previously treated patients with advanced bladder cancer 01 May 2017 AstraZeneca and its global biologics research and development arm, MedImmune, have announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab). Imfinzi is indicated for the treatment of patients with locally advanced or metastatic … Continue reading Top Pharma News | May – June 2017

Advertisements

Top News from 2017 ASCO Annual Meeting

  CancerLinQ®, FDA, NCI Collaborations Offer Opportunities to Advance Oncology Care June 3, 2017 CancerLinQ LLC, a wholly owned nonprofit of ASCO, announced key partnerships with the U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI). The partnership with FDA will use real-world data from CancerLinQ® to help answer questions about the best … Continue reading Top News from 2017 ASCO Annual Meeting

Top 10 Global CROs 2017

Top 10 Global CROs 2017

The global contract research market is growing at a strong rate owing to increasing patent expiration and declining R&D productivity. Furthermore, increasing costs of new product development and revenue loss due to generics have resulted in high demand for contract researching of new biologics and compounds.  The global CRO market is highly consolidated with the … Continue reading Top 10 Global CROs 2017

Amgen Logo

Amgen Submits Applications in the US and Europe for Expanding Current Indication For XGEVA (denosumab) to Include Patients with Multiple Myeloma

April 4, 2017 Amgen has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and an application for a variation to the marketing authorization to the European Medicines Agency (EMA) for XGEVA® (denosumab). These submissions to regulatory authorities seek to expand the currently approved XGEVA indication for the prevention of skeletal-related events … Continue reading Amgen Submits Applications in the US and Europe for Expanding Current Indication For XGEVA (denosumab) to Include Patients with Multiple Myeloma

Cost of Medicines in Context

Cost of Medicines in Context

Prescription drug spending is making up only 9.5% of total healthcare cost. Learn more about what is behind the cost of medicines.

Bristol-Myers Squibb Collaborates with Foundation Medicine to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents

March 30, 2017 Bristol-Myers Squibb Company and Foundation Medicine has announced a collaboration that leverages comprehensive genomic profiling and molecular information solutions of Foundation Medicine to identify predictive biomarkers like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) in patients enrolled across clinical trials investigating cancer immunotherapies of Bristol-Myers Squibb. Biomarkers can be used to characterize a … Continue reading Bristol-Myers Squibb Collaborates with Foundation Medicine to Identify Predictive Biomarkers Across Multiple Tumor Types and Immunotherapy Agents

Novartis logo - luca dezzani

EU approves Novartis drug combination Tafinlar + Mekinist for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)

APR 03, 2017 Novartis has announced the European Commission has approved Tafinlar®(dabrafenib) in combination with Mekinist® (trametinib) for treating patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC). This approval marks the first targeted treatment approved for the patient population, who previously had few treatment options, in all 28 member states of the … Continue reading EU approves Novartis drug combination Tafinlar + Mekinist for BRAF V600-positive advanced non-small cell lung cancer (NSCLC)

Top Pharma News - IgeaHub

Top Pharma News | March – April 2017

Bristol-Myers Squibb Planning Collaboration with GRAIL on Blood-Based Cancer Screening March 1, 2017 Bristol-Myers Squibb Company plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is to detect cancer early when it potentially can be cured. GRAIL aims to develop highly sensitive blood tests that detect cancer in its early … Continue reading Top Pharma News | March – April 2017

Best Pharmaceutical Companies at a Glance: Gilead

Best Pharmaceutical Companies at a Glance: Gilead

Gilead is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicine with focus on virology, hepatology, hematology, oncology, cardiovascular, inflammation and respiratory diseases. The company recorded sales of $30.4 billion in 2016 a decrease by 7% compared to $32.6 billion in 2015 primarily due to a decrease in antiviral product sales. The earnings … Continue reading Best Pharmaceutical Companies at a Glance: Gilead

FDA Approves Tesaro’s niraparib for ovarian cancer

March 27, 2017 The FDA has given approval to Tesaro for the use of its PARP drug niraparib, which will now be marketed as Zejula as a maintenance therapy for the treatment of recurrent ovarian cancer. Tesaro had argued that the efficacy data for niraparib qualified for an approval for use in patients who are either … Continue reading FDA Approves Tesaro’s niraparib for ovarian cancer